Contrast Region: Nephmadness 2018

Acute kidney injury was first linked to iodinated contrast over 6 decades ago. However, safer contrast agents, better patient selection, and greater awareness of the inherent confounding have resulted in the questioning of the existence of contrast nephropathy. We explore this question as well as the risks of iodinated contrast vs gadolinium-based contrast in patients with severe CKD in this region. Check out the full #NephMadness Contrast Region here

Target Audience

  • Physicians
METHOD OF PARTICIPATION:
  • Read the educational summary for the Contrast Region here
  • Make sure you completed a bracket with your predictions of what concepts are the most important or most impactful here
  • Participate in social media (Twitter, Instagram, Facebook, blogs) discussions about these concepts, sharing your opinions of what is the most important or impactful to you in nephrology.  
  • Login or create an account to this site and complete the evaluations and download certificate.

Learning Objectives

After participation in this activity, learners will be able to:

  • Debate the nephrotoxic potential of iodinated contrast with regards to hemodynamics, tubular toxicity, and free radical damage
  • Review the options for imaging in advanced chronic kidney disease stage IV (gadolinium, iodinated contrast) and discuss potential alternative therapeutic agents being considered
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
03/15/2018
Course expires: 
06/15/2018
Cost:
$0.00
Parent activity set: 
Rating: 
0

Anitha Vijayan, MD
Professor of Medicine
Washington University School of Medicine 
St. Louis, MO 
Disclosure: Honoraria: Sanofi (AKI/Tumor lysis) and NxStage (AKI/SLED).  

Planning Committee Disclosures

Natasha N. Dave
Chief Nephrology Fellow 
Baylor College of Medicine
Houston, TX
Disclosure: Has no financial relationships with commercial interest(s).

Paul M. Palevsky, MD, FNKF
Chief, Renal Section (VAPHS); Professor of Medicine
VA Pittsburgh Healthcare System;
University of Pittsburgh
Pittsburgh, PA
Disclosure:  Honroaria: Novartis (AKI); Baxter (CRRT); GE Healthcare (CA-AKI); Healthspan DX (AKI) 

Rajeev Raghavan, MD
Associate Professor of Medicine
Baylor College of Medicine
Houston, TX 
Disclosure: Has no financial relationships with commercial interest(s).

Matthew A. Sparks, MD
Assistant Professor/Associate Program Director
Duke University Medical Center/Durham VA Medical Center
Durham, NC
Disclosure: Has no financial relationships with commercial interest(s).

Swapnil Hiremath, MD
Nephrologist/ Assistant Professor 
The Ottowa Hospital/University of Ottowa 
Ottowa, Ontario, CAN  
Disclosure: Has no financial relationships with commercial interest(s).  

Danielle Nathan, MA
Professional Education Director
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).

Kathryn Troy, MPH
Professional Education Coordinator
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).

DECLARATION OF DISCLOSURE:

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity.  

If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

UNLABELED/INVESTIGATIONAL USE:

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

The National Kidney Foundation is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.


 

Physician

The National Kidney Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

Accreditation Period

Course opens: 
03/15/2018
Course expires: 
06/15/2018

Price

Cost:
$0.00
Please login or register for a PERC account to take this course.
DISCLAIMER:

The faculty and National Kidney Foundation (NKF) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information contained in this NKF educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments.  This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.